Literature DB >> 17134964

Molecular biology in head and neck cancer.

Ricardo Hitt1, María José Echarri.   

Abstract

Major changes in the treatment of head and neck cancer are possible today because of the knowledge that we have on the molecular biology of these tumors. Different pathways are active in the development of this cancer and field cancerization is a major problem for the cure in early stage disease. Epidermal growth factor signal transduction pathway is now the principal target for this disease. New therapeutic strategies such as monoclonal antibodies and small molecules have appeared, however no more than 20% of the patients have objective responses with these therapies. Consequently, new alternatives of treatment in the basis of the understanding of molecular biology are necessary to increase the number of patients that can be cured in the future.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17134964     DOI: 10.1007/s12094-006-0131-8

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  24 in total

1.  Multiple head and neck tumors: evidence for a common clonal origin.

Authors:  G C Bedi; W H Westra; E Gabrielson; W Koch; D Sidransky
Journal:  Cancer Res       Date:  1996-06-01       Impact factor: 12.701

2.  How many mutations are required for tumorigenesis? Implications from human cancer data.

Authors:  M J Renan
Journal:  Mol Carcinog       Date:  1993       Impact factor: 4.784

Review 3.  A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications.

Authors:  Boudewijn J M Braakhuis; Maarten P Tabor; J Alain Kummer; C René Leemans; Ruud H Brakenhoff
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

Review 4.  The role of STATs in transcriptional control and their impact on cellular function.

Authors:  J Bromberg; J E Darnell
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

5.  A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization.

Authors:  M Partridge; S Pateromichelakis; E Phillips; G G Emilion; R P A'Hern; J D Langdon
Journal:  Cancer Res       Date:  2000-07-15       Impact factor: 12.701

6.  Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo.

Authors:  J R Grandis; S D Drenning; Q Zeng; S C Watkins; M F Melhem; S Endo; D E Johnson; L Huang; Y He; J D Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

7.  Recurrent cytogenetic abnormalities in squamous cell carcinomas of the head and neck region.

Authors:  D L Van Dyke; M J Worsham; M S Benninger; C J Krause; S R Baker; G T Wolf; T Drumheller; B C Tilley; T E Carey
Journal:  Genes Chromosomes Cancer       Date:  1994-03       Impact factor: 5.006

Review 8.  Mutant epidermal growth factor receptors as targets for cancer therapy.

Authors:  I A J Lorimer
Journal:  Curr Cancer Drug Targets       Date:  2002-06       Impact factor: 3.428

9.  Clonal origin of bladder cancer.

Authors:  D Sidransky; P Frost; A Von Eschenbach; R Oyasu; A C Preisinger; B Vogelstein
Journal:  N Engl J Med       Date:  1992-03-12       Impact factor: 91.245

10.  Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma.

Authors:  P P Leong; B Rezai; W M Koch; A Reed; D Eisele; D J Lee; D Sidransky; J Jen; W H Westra
Journal:  J Natl Cancer Inst       Date:  1998-07-01       Impact factor: 13.506

View more
  3 in total

1.  Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients.

Authors:  C Ulrich; J Bichel; S Euvrard; B Guidi; C M Proby; P C M van de Kerkhof; P Amerio; J Rønnevig; H B Slade; E Stockfleth
Journal:  Br J Dermatol       Date:  2007-12       Impact factor: 9.302

2.  Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.

Authors:  Minghui Zhang; Xiaosan Zhang; Shu Zhao; Yan Wang; Wenyu Di; Gangling Zhao; Maopeng Yang; Qingyuan Zhang
Journal:  Target Oncol       Date:  2014-12       Impact factor: 4.493

3.  Survivin expression, HPV positivity and microvessel density in oropharyngeal carcinomas and relationship with survival time.

Authors:  Ebru Tastekin; Vuslat Yurut Caloglu; Nilufer Kilic Durankus; Necdet Sut; Gorkem Turkkan; Nuray Can; Fulya Oz Puyan; Murat Caloglu
Journal:  Arch Med Sci       Date:  2016-04-27       Impact factor: 3.318

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.